Table 2:

Simplified comparison between the PRIMO and OPERA studies [7, 8].

Characteristics	PRIMO (Multinational)	OPERA (Chinese)	Comments
n	227 (115/112)	N = 60 (30/30)
eGFR (ml/min/1.73 m2)	31 (24–43)	19.7 (16–30.6)	Opera mean (IQR)
LVH	Mild moderate or no LVH	Moderate to severe LVH
Diagnosis	MRI/echo	Echo	MRI (primary endpoint)
Initial dosing	Mostly 2 µg paricalcitol/day	Mostly 1µg paricalcitol/day (2 µg if >500 pg/ml)	48 weeks PRIMO; 52 weeks OPERA
iPTH absolute basal values (pg/ml)	Paricalcitol group: 100 (66–174); placebo group: 106 (71–153)	Paricalcitol group: 156 (108–235) Placebo group: 129 (121–176) Post-paricalcitol: 51 (37–78)
ΔLVMI (g/m2)	Paricalcitol group 0.34 g/m2 (−0.14–0.83) versus placebo group −0.07 g/m2 (−0.55–0.42 g/m2); adjusted least squares mean (95% CI)	Paricalcitol group −2.59 g/m2 (−6.13–0.32) versus placebo group −4.85 g/m2 (−9.89–1.10); median (IQR)	NS
Hypercalcaemia	23%	43.3 versus 3.3%	OPERA 70% on calcium-based phosphate binders
Other	Lower hospitalization rate	Lower hospitalization rate (no CV events in paricalcitol group)	Underpowered for events (OPERA 0 versus 6)

IQR: interquartile range; LVMI: left ventricular mass index; MRI: magnetic resonance image; NSL not significant.